The following payment options are available to all clients: • Premium funding • BPAY • Remittance advice • Over the phone

Payment Options

The following payment options are available to all clients:

Premium funding

Lockton offers specialised and tailored premium funding options to clients through our in-house funding experts. Our in-house premium funding experts are committed to the highest standards of excellence, and have years of experience managing tailored solutions to individual needs.

The benefits of premium funding include:

  • Conserve cash flow

  • Interest cost is usually tax deductible

  • Working capital can be utilised to generate additional income that may offset part of the funding cost

  • Provides an alternative source of capital rather than the traditional facilities such as bank overdrafts, which are usually secured by business or personal assets

  • Premium funding may be considered as an “off balance sheet” loan

  • Premium funding loans are generally not secured by business assets, such as a charge over the company or directors’ guarantees but rely on the unused portion of the insurance premium as security in the event of default

  • As cash flow is improved by premium funding, the client can more easily afford a complete insurance and risk management program which may avoid under-insuring and therefore help to protect the business

Contact your broker to arrange a premium funding quotation.
 

BPAY

You can pay your premiums via BPAY through your bank’s website using the biller code and customer reference number provided on your invoice or statement.
 

Remittance advice

You can return your remittance advice to our office including your credit card details, a money order, or cheque for payment.

Please note there is a credit card fee of 1.04% for Visa and MasterCard. We do not accept American Express.
 

Over the phone

We accept credit card payments over the phone, you just need to provide your card number, expiration date, and CCV code as well as your invoice number for payment.

Please note there is a credit card fee of 1.04% for Visa and MasterCard. We do not accept American Express.

Latest from Lockton

Australia’s trade credit insurance (TCI) market is showing renewed momentum, supported by improved underwriting confidence, increased product availability and a growing recognition of trade credit insurance as a strategic risk management tool.Australia’s Trade Credit Insurance Market Regains Momentum, but with Discipline

How risk is changing across hotel assets

Australia’s hotel sector remains a compelling investment class, but as assets become more complex, so too does the risk profile that underpins them. Hotel risk does not exist neatly within development, ownership or operations, it spans all three.
Decisions made during design and construction can influence how an asset performs operationally and how it is viewed by insurers long after completion. 
Australia’s hotel sector remains a compelling investment class, but as assets become more complex, so too does the risk profile that underpins them. Hotel risk does not exist neatly within development, ownership or operations, it spans all three.
Decisions made during design and construction can influence how an asset performs operationally and how it is viewed by insurers long after completion.

NSW releases new Code of Practice for healthcare and social assistance

NSW is the first state to adopt the Healthcare and Social Assistance Industry Code of Practice. Learn what it means for WHS compliance from 20 February 2026.NSW is the first state to adopt the Healthcare and Social Assistance Industry Code of Practice. Learn what it means for WHS compliance from 20 February 2026.

Re-thinking D&O liability for life sciences companies

Life Sciences state of play
In the fast-moving world of medtech, biotech, and pharmaceuticals, directors and executives navigate a landscape defined by scientific complexity, regulatory scrutiny, and heightened stakeholder expectations. 

These factors have led to a profound shift in how Directors & Officers (D&O) exposure is understood, moving from a narrow insurance consideration to a broader reflection of governance, disclosure, and enterprise risk dynamics.
Life Sciences state of play
In the fast-moving world of medtech, biotech, and pharmaceuticals, directors and executives navigate a landscape defined by scientific complexity, regulatory scrutiny, and heightened stakeholder expectations. 

These factors have led to a profound shift in how Directors & Officers (D&O) exposure is understood, moving from a narrow insurance consideration to a broader reflection of governance, disclosure, and enterprise risk dynamics.
See all news and insights